North America Cancer Therapy Market - Growth, Trends, and Forecasts (2017 - 2022)

The North American cancer therapy market is expected to grow at a CAGR of 15.5 % and reach USD 15.2 billion by 2019.

North America Cancer Therapy Market-Market Dynamics

The report details several factors driving and restraining the market, some of which are listed below.


Rise in cancer incidence

Increasing access to modern therapeutics

Increasing geriatric population

Increase in innovations, improvements and approvals


The major restraints to the growth of the market are the high prices of therapy, change in reimbursement policies, and challenges faced in clinical trials.

The cancer therapy market is segmented based on therapy into targeted cancer therapy (hormone therapy, signal transduction inhibitors, gene expression modulators, apoptosis inducers, etc.), immunotherapy (monoclonal antibodies, cancer vaccines, non-specific immunotherapy), and chemotherapy.

Several major players are implementing innovations, strategies, and new product launches to gain a competitive edge. Some of these companies are:

AstraZeneca PLC

Chugai Pharmaceutical Co., Ltd.

Genentech Inc.

GlaxoSmithKline PLC

GPC Biotech AG

OSI Pharmaceuticals, Inc.

Key Deliverables in the Study

Market analysis for the North American cancer therapy market, with region-specific assessments and competition analysis on the global and regional scale.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market.

Identification and analysis of the macro and micro factors that affect the North American cancer therapy market.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is growing and to also identify the regions that are still untapped.

1. Introduction

2. Executive Summary

2.1 Cancer Drug Market Review

2.2 Research Methodology

3. Market Dynamics

3.1 Market Drivers

3.1.1 Rise in Cancer Incidence and Access to Modern Therapeutics

3.1.2 Increasing Aging Population

3.1.3 Innovations, Improvements and Approvals

3.2 Market Restraints

3.2.1 High Price of Therapy

3.2.2 Change in Reimbursement Policies

3.2.3 Challenges Encountered in Clinical Trials

4. Types of Cancer

4.1 Blood Cancer

4.2 Bone Cancer

4.3 Brain Cancer

4.4 Breast Cancer

4.5 Digestive/ Gastrointestinal Cancer

4.6 Endocrine Cancer

4.7 Eye Cancer

4.8 Genitourinary Cancer

4.9 Gynecologic Cancer

4.10 Head & Neck Cancers

4.11 Respiratory/Lung Cancer

4.12 Skin Cancer

5. Cancer Treatment Types

5.1 Surgery

5.2 Chemotherapy

5.3 Radiation Therapy

5.4 Targeted Therapy

5.5 Immunotherapy (Biologic Therapy)

5.6 Hormonal Therapy

5.7 Hyperthermia

5.8 Stem Cell Transplant

5.9 Other Therapy

6. Cancer Therapy Market

6.1 North America Market Trend

6.2 Market Size and Share Estimation

7. Market Segmentation

7.1 Targeted Cancer Therapeutics

7.1.1 Introduction

7.1.2 Targeted Cancer Therapy vs. Chemotherapy

7.1.3 Targets for Targeted Cancer Therapy

7.1.4 Types of Targeted Cancer Therapy Hormone Therapy Signal Transduction Inhibitors Gene Expression Modulators Apoptosis Inducers Angiogenesis Inhibitors Immunotherapy Monoclonal Antibodies

7.1.5 Limitations of Targeted Cancer Therapy

7.1.6 Current and Future Analysis

7.1.7 List of Selected Targeted Therapy Drugs

7.1.8 Products in Pipeline

7.1.9 Major Players in the Market Roche/ Genentech Company Profile Products in the Market Financial Overview Novartis Company Profile Products in the Market Financial Overview Bristol-Myers Squibb Company Profile Products in the Market Financial Overview

7.2 Immunotherapy

7.2.1 Introduction of Immunotherapy

7.2.2 Types of Cancer Immunotherapy Monoclonal Antibodies Naked Monoclonal Antibodies Conjugated Monoclonal Antibodies Radiolabeled Antibodies Chemolabeled Antibodies Cancer Vaccines Vaccines to Help Prevent Cancer Vaccines to Help Treat Cancer Non-Specific Immunotherapy Interferons Interleukins

7.2.3 Current and Future Analysis

7.2.4 Limitations of Immunotherapy

7.2.5 List of Selected Drugs

7.2.6 Major Players in the market Dendreon Company Profile Products in the Market Financial Overview Galena Biopharma Company Profile Products in the Market Financial Overview NewLink Genetics Company Profile Products in the Market Financial Overview Peregrine Pharmaceuticals Company Profile Products in the Market Financial Overview Inovio Pharmaceuticals Profile in the Market Financial Overview

7.3 Hormone Therapy

7.3.1 Introduction of Hormone Therapy

7.3.2 Aromatase Inhibitors

7.3.3 Selective Estrogen Receptor Modulators

7.3.4 Estrogen Receptors Down regulators

7.3.5 Hormone Therapy vs. HRT

7.3.6 Forms of Hormone Therapy Nasal Spray Pills or Tablets, Taken by Mouth Skin Gel Skin Patches Vaginal Creams or Vaginal Tablets Vaginal Ring

7.3.7 Current and Future Analysis

7.3.8 Products in the Current Market

7.4 Chemotherapy

7.4.1 Introduction of Chemotherapy

7.4.2 Types of Agents Alkylating Agents Anti-Metabolites Anti-Microtubule Agents Topoisomerase Inhibitors Cytotoxic Antibiotics

7.4.3 Current and Future Analysis

7.4.4 Products in Market

7.4.5 Chemotherapy Regimens Breast Cancer Hodgeking's Disease Germ Cell Tumor Stomach Cancer Bladder Cancer Lung Cancer

8. Market Segmentation, Based on Country

8.1 US

8.2 Mexico

8.3 Canada

9. Competitive Landscape

9.1 Introduction

9.2 New Product Launch

9.3 Strategic Development

9.4 Mergers, Acquisitions

9.5 Market Share Analysis

10. Company Profiles

10.1 AstraZeneca PLC

10.2 Chugai Pharmaceutical Co., Ltd.

10.3 Genentech Inc.

10.4 GlaxoSmithKline PLC

10.5 GPC Biotech AG

10.6 OSI Pharmaceuticals, Inc.

11. Appendix

11.1. Abbreviations

11.2. Sources

11.3. Bibliography

11.4. Disclaimer

Content are not available

Choose License Type